AdAlta Ltd’s (ASX:1AD) is focused on developing treatments for fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF), and this strategy will be outlined at this month’s Proactive CEO Sessions.
The biotechnology company aims to develop and commercialise its i-body technology platform that has generated a pipeline of i-bodies, with an initial focus on treating fibrotic diseases.
AdAlta’s CEO and director Sam Cobb will present at the Sydney CEO Session on Monday, February 18 and at the Melbourne session on Tuesday, February 19.
Cobb is the founding CEO of AdAlta and has more than 15 years’ experience in business development and commercialisation of early-stage scientific technologies.
IPF: irreversible, unpredictable and incurable
IPF is an irreversible, unpredictable and incurable disease with at least 1,500 Australians diagnosed each year. Only 20% of patients diagnosed survive five years.
AdAlta late last month announced improved cell line development results for its lead i-body fibrosis candidate, AD-214, which it is advancing toward clinical development.
Results ahead of expectations
Results are now above previously reported expression levels, at 3 grams per litre (g/L), up from the 1g/L reported in October 2018.
The improved results mean AdAlta remains on track with the development of the manufacturing process for AD-214.
It is on target to deliver Good Laboratory Practice (GLP) material for its four-week non-human primate toxicology study, which is expected to begin in July 2019 and be completed in second half of the year.
AdAlta is also on track to deliver Good Manufacturing Practice (GMP) material for its phase I human study which is expected to begin in January 2020.
Register for the CEO Sessions today to find out more.
Also featuring at both sessions will be Kazia Therapeutics Ltd (ASX:KZA) and Peninsula Energy Ltd (ASX:PEN) while Theta Gold Mines Ltd (ASX:TGM) is on the Sydney program and Anatara Lifesciences Ltd (ASX:ANR) is on the Melbourne program.